CytomX is developing the next generation of highly targeted antibody therapeutics.
Read More

Recent News


CytomX Therapeutics to Present Data from Anti-Jagged Probody Program at Upcoming AACR Annual Meeting 2014

More Events >


CytomX Announces Global Strategic Collaboration with Pfizer to Develop and Commercialize Multiple Probody™-Drug Conjugates in Oncology

More Events >